# Detechgene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/detechgene

- Industry: Medical Devices & Equipment
- Headquarters: Cologne, Germany
- Website: www.detechgene.de/
- Total disclosed funding: $3.6M
- Latest round: Seed (May 27, 2025)
- Investors on record: 7

## About

Detechgene GmbH, headquartered in Cologne, Germany, specializes in precision diagnostics, developing rapid testing solutions for pathogen detection. Their innovative products serve a diverse range of users, including healthcare facilities and individual consumers.Established in 2022, Detechgene GmbH focuses on precision diagnostics with a product lineup that includes advanced testing solutions. The company has engaged in two deals to date, with the latest funding round being a Seed round in August 2025, where they raised EUR 3.2 million led by neoteq Ventures. The founder's background is not detailed in the available information.Detechgene specializes in precision diagnostics through its innovative testing products, including the DetechStamp and DetechChip, which enable the rapid detection of pathogens. These products utilize nucleic acid detection technology to deliver laboratory-quality results comparable to those of PCR tests within a mere 20 minutes. Detechgene's offerings are designed for diverse end users, ranging from clinics performing bedside diagnostics to households testing for common parasites and infectious diseases. Additionally, the company's solutions are tailored for healthcare researchers seeking to enhance their laboratory environments and for pet owners monitoring their animals’ health. Detechgene's products are marketed globally, catering to various geographical markets without limitation to its native region in Germany.Detechgene generates revenue through direct sales to consumers and partnerships with healthcare providers and researchers. The company’s flagship products, such as the DetechStamp and DetechChip, are offered in a straightforward transaction structure that allows healthcare facilities and private individuals to purchase them outright. Customers benefit from the convenience of portable, pocket-sized testing solutions, which facilitate diagnostics in diverse settings. The streamlined nature of the business model points to a focus on accessibility and widespread adoption across multiple sectors, including clinical environments and home testing. The emphasis on delivering high-precision diagnostics positions Detechgene favorably within the healthcare market.In August 2025, Detechgene GmbH raised EUR 3.2 million in Seed funding to expand the market reach of its products. The company plans to leverage this funding to introduce new products and enhance its presence in existing markets while exploring entry into additional regions. Specific details regarding new product launches and targeted geographic areas for growth are not disclosed.

## Funding rounds

- Seed, May 27, 2025, $3.6M — NRW Bank, Campus Capital, neoteq Ventures, Optima Vermögensverwaltung GmbH, Dr. Weinberger Management & Consult GmbH, Meerkat, Aquarius Invest GmbH
- Seed, Jun 1, 2021 — NRW Bank, neoteq Ventures

## Investors

- NRW Bank — Seed
- neoteq Ventures (https://capitalatlas.ai/funds/neoteq-ventures) — Seed
- Campus Capital (https://capitalatlas.ai/funds/campus-capital) — Seed
- Optima Vermögensverwaltung GmbH — Seed
- Dr. Weinberger Management & Consult GmbH — Seed
- Meerkat (https://capitalatlas.ai/funds/meerkat) — Seed
- Aquarius Invest GmbH — Seed